The U.S. Food and Drug Administration said it has granted approval for Ferring Pharmaceuticals Inc.'s fecal microbiota product Rebyota. The approval is for the prevention of recurrence of Clostridioides difficile infection or CDI in individuals 18 years of age and older. Rebyota will be used after an individual has completed antibiotic treatment for recurrent CDI.
from RTT - Top Story https://ift.tt/k6AHnxq
via IFTTT
from RTT - Top Story https://ift.tt/k6AHnxq
via IFTTT
Comments
Post a Comment